… a cost-effective method to screen for multiple cancers simultaneously. The primary objective
of this study was to investigate the cost-effectiveness … become more cost effective over time. …

… Moreover, this analysis supports the current guideline that natalizumab is not a … because
of the PML adverse effect. Natalizumab was not a cost-effective treatment in this analysis. …

Objective The aim of the current study was to evaluate the 2-year cost-utility ratio between
tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD) first …

… We sought to perform a cost-utility analysis of all aforementioned interventions using current
and thorough cost estimates along with current and robust clinical efficacy and health utility …

… the cost of quality-adjusted life years (QALY) and the cost of … The purpose of this article is
to present cost-utility analysis as a … of cost effectiveness, along with a discussion of two cost-…

… A cost–utility analysis (CUA) is a type of CEA in which benefits are measured in terms of
quality-adjusted life-years (QALYs) to allow comparison of the relative efficiency of health-care …

… We performed a cost-utility analysis to address the current knowledge gap regarding the
cost-effectiveness of screening strategies for steatohepatitis and NASH-fibrosis, two advanced …

… Although an RCT provides a robust causal estimate of the intervention effect, a single trial
may not provide sufficient evidence on which to base a decision on cost effectiveness [33]. For …

… We focus on cost-utility analysis, which is a special case of cost-effectiveness analysis where
… Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. …

… cost-effectiveness data that should reduce such uncertainty. We report a cost-utility analysis
of … report the probability that the intervention might be cost effective. Dividing the difference in …